Hims & Hers Health, Inc. · NYSE:HIMS
Hims & Hers Health — Q4 2022 Earnings Presentation
32 slides from Hims & Hers Health's earnings presentation, February 2023
Slide 1: Hims & Hers Investor Presentation February 2023
hims 3 hers Investor Presentation February 2023
Slide 2: Disclaimer
FINANCIALS Disclaimer This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking
Slide 3: Feeling good in your body & mind transforms how you show up
INTRODUCTION Feeling good in your body & mind transforms how you show up in life That's why we're on a mission to help the world feel great through the power of better health
Slide 4: Bringing together consumer brands, technology companies and healthcare
Introduction 4 Bringing together the most Remember to take your medication at... valuable elements of consumer brands, technology companies and healthcare to deliver an experience unlike anything in market
Slide 5: An entirely new platform that makes feeling great personalized, accessible, affordable
INTRODUCTION The result — an entirely new platform that makes feeling great personalized, accessible, and affordable hims hers
Slide 6: Our unique approach is rapidly scaling with a strong margin profile
Introduction 6 1M+ 1M Our unique approach is Subscribers 3 ’22 rapidly scaling with a 130K strong margin profile ’18 $527M $527M ’22 Revenue $27M ’18 Q4 ’22 110%+ compounded annual growth rate 1 Profitability (3.0%) ’22 90%+ recurring revenue2 Adjusted EBITDA (256%) 75%+ margin4 ’18 gross margin pro
Slide 7: We continue to unlock growth in our immediate markets
INTRODUCTION We continue to unlock growth in our immediate markets and are primed to capture future, underpenetrated opportunities °, as much as 90% of Through normalizing and > 90 7o applicable population innovating, our platform can yet to seek treatment unlock solutions for millions in some condi
Slide 8: Our Strategy
Slide 9: Our team is led by a visionary founder
STRATEGY Our team is led by a visionary founder, with support from a leadership team that has scaled disruptive companies waShLAaAL Andrew Yemi Melissa Soleil Mike Dr. Pat Brian Dudum Okupe Baird Boughton Chi Carroll O'Shaughnessy Chief Executive Officer Chief Financial i Chief Operating Chief Legal
Slide 10: Internal clinical advisory board and healthcare partnerships
STRATEGY 10 An internal clinical advisory board and a breadth of healthcare partnerships drive clinical excellence Medical review Partnerships & affiliations YOchener i#SINAT naCare’ 23: Carbon Health goodpc > 12 leading | High confidence provider recommendations > 7 health | Access to best-in-class
Slide 11: Success derived from execution across four strategic pillars
STRATEGY Success is derived from sound execution across four strategic pillars 1 2 Trusted brand + Consumer-centricity Leadin technology + Proprietary technology stack + Data security & privacy + Feedback & insights-driven platform + Partnerships & ambassadors + Seamless customer experience * Multi-
Slide 12: Building the world's most trusted health & wellness brand
STRATEGY Building the world’s most trusted health & wellness brand is key to attracting & retaining customers Centricity We measure our success by their success. What they need, what they want, and what they want that they didn’t even know they could have. That’s what drives us and why everything we
Slide 13: Our leading technology platform enables customer & provider experience
S T R AT E GY 13 Our leading technology platform enables a customer & provider experience where bilateral insights drive continuous improvements Proprietary Insights driven Seamless tech stack platform customer access Our tech stack operates as a secure buffer With over 10M medical consultations to
Slide 14: Innovative products and services treat each customer differently
STRATEGY Innovative products and services enable us to treat each customer differently — We pursue innovation in personalized care and enable customizable treatment options that make feeling great easy to achieve Fulfillment capabilities fulfillment through 350k+ sq, feet of affiliated facilities We
Slide 15: Clinical excellence drives high quality outcomes
STRATEGY 15 Clinical excellence drives high quality outcomes & reinforces trust in our brand Access 100% board- Quality Safety & efficacy certified 24/7 51k+ Clinical standards platform uptime charts audited for quality in 2022 realtime monitoring of clinical standards Fast & convenient Provider sca
Slide 16: These four pillars come together to create a powerful flywheel
S T R AT EGY 16 Trusted Leading These four pillars Brand Attract & retain t o mer Dema Technology Leverage feedback come together to Cu s n d customers & providers to generate insights create a powerful flywheel t e r trus Insi ghts o n s um Clinical C te r o u tc o m e s Be t Innovative Excellence
Slide 17: Financials
Slide 18: Subscriber footprint and customer engagement drive revenue growth
FINANCIALS Our subscriber footprint and customer engagement drive revenue growth Acquisition Multi-channel brand development Brand ambassadors Partnerships > Retention Customer > experience High clinical > excellence Specialized > content & tools Engagement Multi-month adoption Proprietary product a
Slide 19: Our subscriber base continues to expand
FINANCIALS 19 Our subscriber base continues to expand Subscribers Revenue $s2 $50 $50 1040 o—_5 —_0—_,_ 0 —_5 —— 9 @ £09 single-month subscribers ('000) fo) Monthly online rev. per avg. subscriber’ § EOQ multi-month subscribers (‘000) @ Online revenue ($ millions) 748 @ Wholesale revenue ($ millions
Slide 20: Both new and repeat usage power online revenue growth
FINANCIALS 20 $503 Both new and repeat usage power online revenue growth Aa New online revenue 83%+ | (S$ millions)’ a pen Repeat customer online g | revenue ($ millions)’ ois $258 $141 _ = s7 Es i sl | FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 himsshers
Slide 21: Ability to scale our platform at an attractive margin profile
FINANCIALS This has translated into an ability to scale our platform at an attractive margin profile Annual revenue a ($ millions) 110%+ Gross margin CAGR (percentage) 2018 - 2022 $149 FY 2018 FY 2019 FY 2020 FY 2021 -- 4 209% a 80% 4 83% $527 FY 2022 494% himszhers
Slide 22: Positive Adjusted EBITDA generated in Q4 '22
FINANCIALS Positive Adjusted EBITDA generated in Q4 ’22, and is projected to continue ® Adjusted EBITDA’ ($ millions) $3.9 fo) Adjusted EBITDA margin’ (percentage) ($9.8) (16.4%) Q1'21 Q2’21 Q3’21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Positive Adjusted EBITDA’ expected going forward scale with improving uni
Slide 23: With strong unit economics we're scaling with confidence
FINANCIALS 23 With strong unit economics we're scaling with confidence Q1’19 Cohort > <lyr Q1’22 Cohort less than one year payback’ (in line with our capital allocation framework) $62 $51 $38 $23 — a=» Ga» Gap § = Cumulative Online Gross Profit (Smillions) @ Cumulative Online Gross Profit (millions)
Slide 24: 2023 outlook anticipates strong growth and continued margin improvement
FINANCIALS 2023 outlook anticipates strong growth and continued margin improvement (S$ millions) Revenue YoY growth Adj. EBITDA’ Adj. EBITDA margin’ Q1 2023 $175 - $180 73% - 78% $3 -$6 2% - 3% FY 2023 $735 - $755 39% - 43% $20 - $30 3%-A% 2023 underlying themes Oo © © 85%+ long-term retention” Expa
Slide 25: Our long-term guiding financial principles
FINANCIALS Our long-term guiding financial principles Long-term 2025 profitability targets trajectory Long-term Adjusted Gross margin Revenue of Adjusted EBITDA of EBITDA margin’ in the atleast atleast 20-30% Mid/0's EiMee SIOOM+ IF
Slide 26: Three key components expected to drive future growth
FINANCIALS Three key components are expected to drive future growth Sample initiatives Introduction of new products and services Expand proprietary solutions Expand footprint of addressable conditions y Continued brand Continued!" development a option o > 4 scaling ofthe category capability Expand p
Slide 27: Capital allocation principles will guide future investment
FINANCIALS Capital allocation principles will guide future investment 1 2 3 A Organic growth Maintain a payback Focus on investments Invest in durable expected to be the period’ across our that drive long-term long-term growth rimary growth driver portfolio of less than margin’ expansion channels ly
Slide 28: Margin improvements expected from several areas over time
FINANCIALS Margin improvements are expected to come from several areas over time Q4'22 Long-term goals @) Leverage on G&A and R&D Expense Benefits from scaling platform and efficiency (eo) (oe) @) Operations and Support > = Increased operational efficiency (e] ce] from economics of scale, automation
Slide 29: Non-GAAP Financial Measures
FINANCIALS Non-GAAP Financial Measures In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP measure) and Adjusted EBITDA margin (which is a non-GAAP margin), each as defined below. We use Adjusted EBITDA and Adjusted EBITDA mar
Slide 30: Reconciliation of non-GAAP financial measures
FINANCIALS Reconciliation of non-GAAP financial measures ($ millions, unaudited) Revenue Net Loss Stock-based compensation Depreciation and amortization Acquisition-related costs Impairment of long-lived assets Merger bonuses Warrant expense in connection with Merger Amortization of debt issuance co
Slide 31: Reconciliation of non-GAAP financial measures
FINANCIALS Reconciliation of non-GAAP financial measures ($ millions, unaudited) Revenue Net Loss Stock-based compensation Depreciation and amortization Acquisition-related costs Change in fair value of liabilities Impairment of long-lived assets Merger bonuses Warrant expense in connection with Mer
Slide 32: Sources
APPENDIX Sources In order of appearance: + B. Kim, S. Lee, MJun, H. Chung, S. Oh. Perception of Hair Loss and Education Increases the Treatment Willingness in Patients With Androgenetic Alopecica: A Population-Based Study, 2018, Fig. 1B. Based on a research study with 503 patients with AGA, 92% of t